TY - JOUR
T1 - Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy
T2 - Report from the Italian Multiple Sclerosis Study group
AU - Bertolotto, Antonio
AU - Capobianco, Marco
AU - Amato, Maria Pia
AU - Capello, Elisabetta
AU - Capra, Ruggero
AU - Centonze, Diego
AU - Di Ioia, Maria
AU - Gallo, Antonio
AU - Grimaldi, Luigi
AU - Imberti, Luisa
AU - Lugaresi, Alessandra
AU - Mancinelli, Chiara
AU - Marrosu, Maria Giovanna
AU - Moiola, Lucia
AU - Montanari, Enrico
AU - Romano, Silvia
AU - Musu, Luigina
AU - Paolicelli, Damiano
AU - Patti, Francesco
AU - Pozzilli, Carlo
AU - Rossi, Silvia
AU - Salvetti, Marco
AU - Tedeschi, Gioachino
AU - Tola, Maria Rosaria
AU - Troiano, Maria
AU - Zaffaroni, Mauro
AU - Malucchi, Simona
PY - 2014/2
Y1 - 2014/2
N2 - Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.
AB - Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.
KW - Guidelines
KW - IFNβ
KW - Immunogenicity
KW - Multiple sclerosis
KW - Neutralizing antibodies
UR - http://www.scopus.com/inward/record.url?scp=84893824738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893824738&partnerID=8YFLogxK
U2 - 10.1007/s10072-013-1616-1
DO - 10.1007/s10072-013-1616-1
M3 - Article
C2 - 24374787
AN - SCOPUS:84893824738
SN - 1590-1874
VL - 35
SP - 307
EP - 316
JO - Neurological Sciences
JF - Neurological Sciences
IS - 2
ER -